比较不同剂量缓释丁丙诺啡治疗高风险阿片类药物使用的随机临床试验
这项多中心、随机、双盲临床试验于2021年10月26日至2024年6月26日在美国和加拿大的28个门诊治疗中心开展,纳入寻求治疗的中度或重度阿片类药物使用障碍参与者(注射阿片类药物、使用高剂量阿片类药物或使用芬太尼)。在完成丁丙诺啡诱导和缓释丁丙诺啡起始(第6周)后,参与者按1:1随机接受8次额外100 mg或300 mg缓释丁丙诺啡维持注射。主要终点为第20至38周期间阿片类药物戒断就诊比例≥80%的应答者比例,100 mg组为20.2%(44/218),300 mg组为23.2%(50/216),差异2.6%(95%CI -4.7%至9.9%)。事后分析显示,在每日使用芬太尼、每周使用芬太尼14次或以上、或两者兼有的参与者中,300 mg维持剂量显著优于100 mg。两组缓释丁丙诺啡相关不良事件相似,但注射部位反应在300 mg组更高(差异9.2%,95%CI 3.7%-15.2%)。
要点
- 在总体高风险阿片类药物使用人群中,缓释丁丙诺啡300 mg与100 mg每月维持剂量在第20至38周阿片戒断应答率上无显著差异(23.2% vs 20.2%,差异2.6%,95%CI -4.7%至9.9%)。
- 事后分析中,每日使用芬太尼者300 mg组应答率优于100 mg组(差异11.1%,95%CI 0.4%-21.6%)。
- 事后分析中,每周使用芬太尼14次或以上者300 mg组优于100 mg组(差异12.2%,95%CI 2.4%-22.1%)。
- 每日使用芬太尼且每周使用14次或以上者,300 mg组优于100 mg组(差异15.4%,95%CI 4.6%-26.1%)。
- 注射部位反应在300 mg组更高(差异9.2%,95%CI 3.7%-15.2%),其余缓释丁丙诺啡相关不良事件两组相似,无新安全信号。
适用人群与场景
- 寻求治疗的中度或重度阿片类药物使用障碍患者,且注射阿片类药物、使用高剂量阿片类药物或使用芬太尼。
- 美国与加拿大28个门诊治疗中心。
- 已完成丁丙诺啡诱导和缓释丁丙诺啡起始(第6周)的参与者。
诊断标准与关键阈值
- 主要终点应答者定义:第20至38周期间阿片类药物戒断就诊比例≥80%的参与者。
处置流程与药物剂量
- 完成丁丙诺啡诱导和缓释丁丙诺啡起始(第6周)后,按1:1随机接受8次额外100 mg或300 mg缓释丁丙诺啡维持注射。
- 缓释丁丙诺啡给药途径为注射,频次为每月一次维持注射,共8次额外注射。
研究设计与关键结果
- 多中心、随机、双盲临床试验,28个门诊治疗中心,随机436例,435例接受注射并分析(100 mg组218例,300 mg组217例;平均年龄41.6岁,SD 10.9;男性248例,57.0%)。
- 主要终点:100 mg组应答44/218(20.2%),300 mg组应答50/216(23.2%),Cochran-Mantel-Haenszel差异2.6%(95%CI -4.7%至9.9%)。
- 事后分析:每日使用芬太尼者300 mg组优于100 mg组(差异11.1%,95%CI 0.4%-21.6%);每周使用芬太尼14次或以上者(差异12.2%,95%CI 2.4%-22.1%);两者兼有者(差异15.4%,95%CI 4.6%-26.1%)。
- 两种给药方案下,阿片类药物使用频率从筛查时超过43次降至第3周时少于3次(持续至第38周)。
- 缓释丁丙诺啡相关不良事件两组相似,除注射部位反应在300 mg组更高(差异9.2%,95%CI 3.7%-15.2%)。
- 两种维持剂量均耐受良好,无新安全信号。
证据类型、等级与局限
- 研究类型:多中心、随机、双盲临床试验。
- 事后分析结果需进一步研究验证(原文结论指出300 mg维持剂量可能在重度芬太尼使用者中表现更好,事后分析亚组结果)。
对床旁实践的改变
- 对于高风险阿片类药物使用(包括芬太尼)患者,缓释丁丙诺啡100 mg和300 mg每月维持剂量均有效且耐受良好。
- 作者认为,300 mg维持剂量可能在重度芬太尼使用(每日使用、每周14次或以上、或两者兼有)的个体中表现更好。
- 300 mg组注射部位反应高于100 mg组(差异9.2%,95%CI 3.7%-15.2%),临床使用时应关注注射部位反应。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT04995029
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients with high-risk opioid use may require higher buprenorphine doses to maximize abstinence and retention in treatment.
OBJECTIVE: To compare the efficacy and safety of 100-mg vs 300-mg once-monthly maintenance doses of extended-release buprenorphine among individuals with high-risk opioid use, including fentanyl.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, double-blind clinical trial was conducted from October 26, 2021, to June 26, 2024, at 28 outpatient treatment centers in the US and Canada among treatment-seeking participants with moderate or severe opioid use disorder who injected opioids, used high doses of opioids, or used fentanyl.
INTERVENTIONS: After completing buprenorphine induction and extended-release buprenorphine initiation (week 6), participants were randomized in a 1:1 ratio to receive 8 additional 100-mg or 300-mg extended-release buprenorphine maintenance injections.
MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of responders for weekly opioid use, defined as participants whose percentage of visits with opioid abstinence was 80% or more over weeks 20 to 38. Post hoc analyses were performed to identify any subgroups that might benefit more from the 300-mg than 100-mg extended-release buprenorphine maintenance dose. Adverse events, including injection-site reactions, were reported. Analysis was conducted on an intent-to-treat basis.
RESULTS: Of 436 participants randomized, 435 (mean [SD] age, 41.6 [10.9] years; 248 men [57.0%]) received injections and were analyzed (218 in the 100-mg arm and 217 in the 300-mg arm). There were 44 of 218 responders (20.2%) in the 100-mg arm and 50 of 216 responders (23.2%) in the 300-mg arm (Cochran-Mantel-Haenszel difference, 2.6%; 95% CI, -4.7% to 9.9%). In post hoc analyses, the 300-mg maintenance dose performed significantly better than the 100-mg maintenance dose among participants who used fentanyl daily (difference, 11.1%; 95% CI, 0.4%-21.6%), used fentanyl 14 times or more per week (difference, 12.2%; 95% CI, 2.4%-22.1%), or both (difference, 15.4%; 95% CI, 4.6%-26.1%). With both dosing regimens, the frequency of opioid use decreased from more than 43 instances at screening to fewer than 3 instances by week 3 (through week 38). Extended-release buprenorphine-related adverse events were similar between groups, except for injection-site reactions, which were higher in the 300-mg arm (difference, 9.2%; 95% CI, 3.7%-15.2%). Both maintenance doses were well tolerated with no new safety signals.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, both extended-release buprenorphine maintenance doses were well tolerated and effective among participants with high-risk opioid use. The 300-mg maintenance dose may perform better among individuals with heavy fentanyl use. These results are particularly relevant because individuals with opioid use disorder in North America are increasingly exposed to highly potent synthetic opioids, such as fentanyl, a driver of high levels of opioid overdose deaths.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04995029.
参考来源
- Shiwach R, Le Foll B, Alho H, et al. Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use: A Randomized Clinical Trial. JAMA Netw Open. 2025. PMID: 41405885. doi:10.1001/jamanetworkopen.2025.48043
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。